TNDM Stock Analysis: Buy, Sell, or Hold?
TNDM - Tandem Diabetes Care, Inc.
$15.32
-0.43 (-2.73%)
▼
5d:
-2.79%
30d:
-17.63%
90d:
-18.55%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.8/10
Get Alerted When TNDM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TNDM trading at deep discount. Market pricing in -10.4% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: TNDM trading at deep discount. Market pricing in -10.4% annual earnings decline, creating value opportunity for patient investors.
In-depth Analysis How we analyze
Valuation Analysis: TNDM is currently trading at $15.32, which is considered slightly low relative to its 30-day fair value range of $14.94 to $17.98. From a valuation perspective, the stock is trading at a discount (Forward PE: 196.9) compared to its historical average (273.5). Remarkably, the market is currently pricing in an annual earnings decline of 10.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TNDM is in a strong downtrend. Immediate support is located at $13.95, while resistance sits at $16.50.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $28.88 (+88.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TNDM is in a strong downtrend. Immediate support is located at $13.95, while resistance sits at $16.50.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $28.88 (+88.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$14.94 -
$17.98
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 88.5% below Wall St target ($28.88)
Trading Range Analysis
30-Day Trading Range
$14.94 -
$17.98
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$13.95
Resistance Level
$16.50
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
196.92
Wall Street Target
$28.88
(+88.5%)
Revenue Growth (YoY)
5.5%
Earnings Growth (YoY)
-37.0%
Profit Margin
-9.2%
Valuation Discount vs History
-10.4% cheaper
PE vs Historical
196.9 vs 273.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.4%
(market-implied from PE analysis)
1-Year Target
$13.79
(-10%)
2-Year Target
$12.41
(-19%)
3-Year Target
$11.17
(-27%)
3-Yr Target (if PE normalizes)
(PE: 197→274)
$15.51
(+1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 196.9 to 273.5
Stabilization Target:
$21.28
(+38.9%)
PE Expansion Potential:
+38.9%
Share & Embed Analysis
Last updated: July 02, 2026 10:46 PM ET
Data refreshes hourly during market hours. Next update: 11:46 PM
Data refreshes hourly during market hours. Next update: 11:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNDM showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark David Novara
SELL
187 shares
2026-03-17
Mark David Novara
SELL
2 shares
2026-03-05
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |
Advanced TNDM Option Strategies
Professional options setups generated by AI based on today's TNDM price and gamma walls.
